对于需要住院康复的急性中风在出院后继续使用阿曼塔丁:长期随访研究
Haley R Torr1, Sara Penrod2, Jennifer Cote2
1Department of Pharmacy, Maine Medical Center, Portland, ME.
概括
在住院康复期间,中风患者的阿曼塔丁剂量有所不同. 药物一般耐受良好,大多数患者在出院后继续服用阿曼塔丁,但长期使用策略需要进一步研究.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 康复医学 康复医学 康复医学
背景情况:
- 脑卒中康复通常涉及管理神经系统缺陷和恢复.
- 阿曼塔丁是一种药物,有时用于改善运动功能和减少神经疾病中的疲劳.
研究的目的:
- 描述阿曼塔丁在中风后入院康复治疗的患者的剂量策略,安全性和有效性.
- 分析在中风康复期间的阿曼塔丁处方实践和不良事件.
主要方法:
- 28名接受口服阿曼塔丁中风后治疗的患者进行了回顾性,单中心的队列研究.
- 收集关于阿曼塔丁剂量,药物不良影响和恢复轨迹变化的数据.
主要成果:
- 最常见的阿曼塔丁初始剂量是每天两次100毫克;在康复期间,剂量有显著的变化.
- 在57%的患者中发现了21种潜在的不良事件,其中38%发生在剂量减少后.
- 对于79%的患者,阿曼塔丁在出院时被处方,每天或每天两次剂量可变.
结论:
- 在住院中风康复期间的阿曼塔丁剂量非常可变.
- 阿曼塔丁一般耐受良好,大多数患者在出院后继续服用药物.
- 需要进一步的前性研究来指导在急性中风后长期使用阿曼塔丁.
更多相关视频
06:52Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
10.0K
08:53Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
609
相关概念视频
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
